Recently, Porrata et al 1 reported in this journal a retrospective analysis of the absolute lymphocyte count (ALC) in patients with metastatic breast cancer treated with highdose chemotherapy (HD-CT) followed by autologous stem cell transplantation (ASCT). They found that ALC counts of X500 cells/ml on day 15 post-ASCT predicted a significant better overall (OS) and disease-free survival (DFS). A total of 29 patients with metastatic breast cancer were included in two different studies, both using STAMP V as a high-dose treatment regimen (cyclophosphamide 1.5 g/m 2 /day; carboplatin 200 mg/m 2 /day and thiotepa 125 mg/m 2 /day on 4 consecutive days). The ALC threshold for immunologic engraftment was determined at 500 cells/ ml on day 15 of transplantation based on experience with hematologic malignancies. After a median follow-up of 2.25 years for living patients (minimum follow-up 2 years or until death), they reported a significantly better median OS and DFS in the 20 patients with ALC X500 cells/ml than in the nine patients with ALC X500 cells/ml on day 15 post-ASCT (not reached vs 14 months Po0.0001; 24 vs 7 months Po0.0015, respectively).
Recently, we published a phase II study of multiple courses of HD-CT with ASCT in 41 patients with stage IV breast cancer.
2 Our high-dose regimen consists of the same agents as STAMP V, but was administered at different doses over multiple courses. As our patient group was quite similar to the patient group described by Porrata et al, 1 we analyzed the lymphocyte count at day 15 after the last course of HD-CT with ASCT in our patient group. We also analyzed ALC before the start of chemotherapy, because one could argue that the patients with a lower ALC at day 15 post-ASCT already had lower values at the start of therapy because of bone marrow infiltration. These patients could have a worse prognosis owing to tumor invasion in the bone marrow.
A total of 41 patients with advanced hormone refractory breast cancer were included in the study. The treatment started with two FE120C courses (5-fluorouracil 500 mg/ m 2 , epirubicin 120 mg/m 2 and cyclophosphamide 500 mg/ m 2 ) followed by ASCT harvesting. The high-dose treatment consisted of three subsequent courses of 'tiny' CTC (cyclophosphamide 4000 mg/m 2 , thiotepa 320 mg/m 2 and carboplatin 1060 mg/m 2 (target AUC 13.3 mg/ml/min) divided over 4 consecutive days). The second and third courses were planned for day 28 after the previous transplant. Thirty-three of these patients, (seven were unresponsive to FE120C and one patient had an estrogen-receptor positive tumor) received HD-CT, of whom 23 received three courses, seven received two courses and three patients only one course. In all, 29 patients (49%) achieved a complete response, nine a partial response (22%) and three patients (9%) stable disease. There was one therapyrelated death. After a median follow-up of 43 months (range 25-61), the OS and PFS for the patient group treated with HD-CT were 29 and 28%, respectively, with a median duration of 28 and 11 months, respectively. The ALC on day 15 after the last HD-CT course with ASCT was o500 cells/ml in 18 patients, and of these patients 11 had died, three were alive with disease and four showed no evidence of disease. In the patient group with an ALC X500 cells/ml, 10 patients had died and five had no evidence of disease. Survival curves were constructed by the KaplanMeier method and compared by the log-rank test. We found no significant difference in time to progression or death between the patient group with an ALC o500 and X500 cells/ml at day 15 (Figure 1 ). There was also no significant association between survival and ALC before the start of induction therapy, the HD-CT and at day 29 post ASCT. Disappointingly, our data do not show a survival benefit for patients with an ALC X500 cells/ml. Like the study of Porrata et al, our study was small and might lack the power to identify differences.
It is important to study the recovery of cellular immunity after ASCT, as it is possible that antitumor immunity plays a role in controlling minimal residual disease. Recently, we published results of a study with the same chemotherapeutic regimen completed with reinfusion of autologous lymphocytes.
3 In this study, three patients were monitored for immune recovery without reinfusion of lymphocytes. In 11 patients, the stem cells were harvested after FE120C+G-CSF and lymphocytes were harvested after FE120C+GM-CSF+interleukin-2. The patients received stem cells and G-CSF after the first HD-CT; stem cells, G-CSF and lymphocytes after the second; and stem cells, GM-CSF and lymphocytes after the third HD-CT. The study showed that lymphocyte reinfusion had a significant effect on the recovery of CD8+ T cells, but recovery of CD4+ T cells also required GM-CSF for a good and rapid recovery. Whether the rapid recovery of these cells has influence on time to progression should be further investigated.
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